The impact of the UPC on life science companies

Life science companies face unique patent issues, for example concerning interim relief, research and clinical trial exemptions and supplementary protection certificates. Bert Oosting, Andreas von Falck, Stanislas Roux-Vaillard, Stephen Bennett and Daniel Brook examine how these questions will be addressed in the proposed UPC.

Life science companies face unique patent issues, for example concerning interim relief, research and clinical trial exemptions and supplementary protection certificates. Bert Oosting, Andreas von Falck, Stanislas Roux-Vaillard, Stephen Bennett and Daniel Brook examine how these questions will be addressed in the proposed UPC.

Click here to read the article.


Back To Listing

Loading data